Evrysdi is being studied in people from 2 months to 60 years old with Type 1, 2, or 3 spinal muscular atrophy (SMA)
The most common side effects of Evrysdi include:
For infants, Type 1 SMA (infantile-onset):
- runny nose, sneezing, sore throat, and cough (upper respiratory infection)
- lung infection
For children and adults, Type 2 or 3 SMA (later-onset):
These are not all of the possible side effects of Evrysdi. For more information, ask your healthcare provider.
No one stopped taking Evrysdi because of side effects in the main clinical studies after 12 months of taking Evrysdi.